A LinkedIn post from Healthera highlights what it describes as an underused revenue stream for community pharmacies in the U.K. The post emphasizes private, non-NHS treatments such as weight loss, hair loss, acne, and broader men’s and women’s health services as areas of recurring demand and attractive margins.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, the average Healthera-enabled pharmacy generates more than £4,200 from private treatments, though many reportedly have not yet developed a dedicated treatments page. The content suggests that demand already exists, citing millions of consultations delivered annually through community pharmacies as reported by NHS England, but argues that accessibility and promotion remain limiting factors.
The company’s post positions its Healthera Clinic product as a digital platform to manage private treatments end to end, including online discovery, digital consultations, booking, payments, communication, and repeat reminders. This integrated workflow is presented as a way to convert ad hoc walk-in business into a more predictable and recurring revenue stream for pharmacies using the software.
For investors, the post points to a strategic focus on enabling pharmacies to monetize private clinical services beyond traditional dispensing income. If the claimed revenue uplift per pharmacy scales across a larger network of users, this could support higher software adoption, increased transaction volumes, and potentially stronger recurring revenue for Healthera in the digital health and pharmacy-tech segment.
The emphasis on high-demand categories such as weight loss and long-term conditions like hair loss and acne suggests exposure to consumer health trends that may be less constrained by public reimbursement budgets. However, the post does not provide details on customer acquisition costs, pricing, or churn, leaving uncertainty around the sustainability and profitability of this revenue stream for Healthera and its pharmacy partners.